{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:54:09Z","timestamp":1790985249502,"version":"4.1.0"},"reference-count":40,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2010,4,27]],"date-time":"2010-04-27T00:00:00Z","timestamp":1272326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2010,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Malignant ascites is a common manifestation of advanced cancers, and treatment options are limited. The trifunctional antibody catumaxomab (anti\u2010epithelial cell\u2010adhesion molecule x anti\u2010CD3) represents a targeted immunotherapy for the intraperitoneal (i.p.) treatment of malignant ascites secondary to epithelial cancers. In this phase II\/III trial (EudraCT 2004\u2010000723\u201015; NCT00836654), cancer patients (\n                    <jats:italic>n<\/jats:italic>\n                    = 258) with recurrent symptomatic malignant ascites resistant to conventional chemotherapy were randomized to paracentesis plus catumaxomab (catumaxomab) or paracentesis alone (control) and stratified by cancer type (129 ovarian and 129 nonovarian). Catumaxomab was administered as an i.p. infusion on Days 0, 3, 7 and 10 at doses of 10, 20, 50 and 150 \u03bcg, respectively. The primary efficacy endpoint was puncture\u2010free survival. Secondary efficacy parameters included time to next paracentesis, ascites signs and symptoms and overall survival (OS). Puncture\u2010free survival was significantly longer in the catumaxomab group (median 46 days) than the control group (median 11 days) (hazard ratio = 0.254:\n                    <jats:italic>p<\/jats:italic>\n                    &lt; 0.0001) as was median time to next paracentesis (77\n                    <jats:italic>versus<\/jats:italic>\n                    13 days;\n                    <jats:italic>p<\/jats:italic>\n                    &lt; 0.0001). In addition, catumaxomab patients had fewer signs and symptoms of ascites than control patients. OS showed a positive trend for the catumaxomab group and, in a prospectively planned analysis, was significantly prolonged in patients with gastric cancer (\n                    <jats:italic>n<\/jats:italic>\n                    = 66; 71\n                    <jats:italic>versus<\/jats:italic>\n                    44 days;\n                    <jats:italic>p<\/jats:italic>\n                    = 0.0313). Although adverse events associated with catumaxomab were frequent, they were manageable, generally reversible and mainly related to its immunologic mode of action. Catumaxomab showed a clear clinical benefit in patients with malignant ascites secondary to epithelial cancers, especially gastric cancer, with an acceptable safety profile.\n                  <\/jats:p>","DOI":"10.1002\/ijc.25423","type":"journal-article","created":{"date-parts":[[2010,4,28]],"date-time":"2010-04-28T15:08:33Z","timestamp":1272467313000},"page":"2209-2221","source":"Crossref","is-referenced-by-count":484,"title":["The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II\/III trial"],"prefix":"10.1002","volume":"127","author":[{"given":"Markus M.","family":"Heiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Murawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Koralewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elzbieta","family":"Kutarska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olena O.","family":"Kolesnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir V.","family":"Ivanchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander S.","family":"Dudnichenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birute","family":"Aleknaviciene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturas","family":"Razbadauskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ganea\u2010Motan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tudor","family":"Ciuleanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Wimberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Schmittel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Schmalfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Burges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horst","family":"Lindhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Lahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon L.","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,8,26]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800830104"},{"key":"e_1_2_6_3_2","first-page":"1","volume-title":"ASCO curriculum: optimizing cancer care. The importance of symptom management","author":"Muir JC","year":"2001"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl499"},{"key":"e_1_2_6_5_2","first-page":"109","article-title":"The pathogenesis of malignant ascites","volume":"134","author":"Tamsma J","year":"2007","journal-title":"Cancer Treat Res"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2354.1995.tb00090.x"},{"key":"e_1_2_6_7_2","first-page":"2392","volume-title":"Cancer: principles and practice of oncology","author":"Hostetter RB","year":"2005"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.11.018"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-198606000-00009"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2006.00777.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(98)00037-2"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/clon.2002.0135"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.8.2526"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1237"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603881"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2003.08.026"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0043"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2303.1992.tb00033.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/dc.2840090509"},{"key":"e_1_2_6_20_2","first-page":"4105","article-title":"The epithelial glycoprotein 2 (EGP\u20102) promoter\u2010driven epithelial\u2010specific expression of EGP\u20102 in transgenic mice: a new model to study carcinoma\u2010directed immunotherapy","volume":"61","author":"McLaughlin PM","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.206.31"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21165"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2769"},{"key":"e_1_2_6_24_2","first-page":"1","article-title":"A technique for the measurement of attitudes","volume":"140","author":"Likert R","year":"1932","journal-title":"Arch Psychol"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1159\/000055374"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930315)71:6<2027::AID-CNCR2820710617>3.0.CO;2-C"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1996.4529"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(91)90467-R"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0748-7983(97)93077-8"},{"key":"e_1_2_6_30_2","first-page":"3917","article-title":"The past, the present and future of the OK\u2010432 therapy for patients with malignant effusions","volume":"18","author":"Katano M","year":"1998","journal-title":"Anticancer Res"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.04.028"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.07.015"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10562"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052985"},{"key":"e_1_2_6_35_2","first-page":"16","article-title":"General aspects of cytokine\u2010release syndrome: timing and incidence of symptoms","volume":"25","author":"Jeyarajah DR","year":"1993","journal-title":"Transplant Proc"},{"key":"e_1_2_6_36_2","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine\u2010release syndrome in patients with B\u2010cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti\u2010CD20 monoclonal antibody (rituximab. IDEC\u2010C2B8)","volume":"94","author":"Winkler U","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_37_2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.3036","article-title":"Safety of catumaxomab: cytokine\u2010release\u2010related symptoms as a possible predictive factor for efficacy in a pivotal phase II\/III trial in malignant ascites","volume":"27","author":"Bokemeyer C","year":"2009","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_38_2","first-page":"254","article-title":"Important role of proinflammatory cytokines\/other endogenous substances in drug\u2010induced hepatotoxicity: depression of drug metabolism during infections\/inflammation states, and genetic polymorphisms of drug\u2010metabolizing enzymes\/cytokines may markedly contribute to this pathology","volume":"12","author":"Prandota J","year":"2005","journal-title":"Am J Ther"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.1999.0945"},{"key":"e_1_2_6_40_2","first-page":"4013","article-title":"Characterization of human IgG antimouse antibody in patients with B\u2010cell malignancies","volume":"9","author":"DeNardo GL","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19990219)84:1<62::AID-IJC12>3.0.CO;2-T"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.25423","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.25423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T20:03:43Z","timestamp":1697486623000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.25423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,26]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["10.1002\/ijc.25423"],"URL":"https:\/\/doi.org\/10.1002\/ijc.25423","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,26]]}}}